NCT06851845View on ClinicalTrials.gov

Clinical Outcomes of C3 Glomerulopathy and IC-MPGN in Russia: Hybrid Retrospective - Prospective Study

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

February 1, 2026

Primary Completion Date

February 1, 2028

Study Completion Date

February 1, 2028

Conditions
Kidney Diseases
Interventions
OTHER

No intervention

Patients will receive medical care in accordance with the routine practice of disease treatment

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY